Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Updates for media on the latest products, offerings and developments across our business.
Jul 5, 2022
91Ï㽶ÊÓƵ’s new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.
Jun 29, 2022
91Ï㽶ÊÓƵ today announced that it has expanded its primary packaging capabilities at its clinical supply facility in Shiga, Japan, through the installation of a high-speed blister packaging line to complement its existing automated bottling line.
Jun 16, 2022
91Ï㽶ÊÓƵ today announced that company experts will be speaking on current clinical market trends and strategies at two upcoming conferences: Clinical Trial Supply New England; and Clinical Trial Supply Europe.
Jun 9, 2022
91Ï㽶ÊÓƵ today welcomed the recent announcement by Phathom Pharmaceuticals that the U.S. Food and Drug Administration has approved both VOQUEZNAâ„¢ TRIPLE PAKâ„¢ and VOQUEZNAâ„¢ DUAL PAKâ„¢ for the treatment of Helicobacter pylori infection in adults.
Jun 7, 2022
91Ï㽶ÊÓƵ and MigVax today announced that they have signed a development agreement to leverage 91Ï㽶ÊÓƵ’s proprietary Zydis® Bio orally disintegrating tablet technology for delivering the MigVax-101 vaccine.
May 19, 2022
91Ï㽶ÊÓƵ today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.
May 16, 2022
The UpTempo Virtuoso platform streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.
May 11, 2022
Ethicann today announced that it is to commence full CGMP manufacturing scale-up of its proprietary THC 2.7 mg : CBD 2.5mg Zydis® sublingual ODT to treat MS spasticity.
Apr 28, 2022
91Ï㽶ÊÓƵ today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
